T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof

Patent metadata

Field	Value
Publication number	US-11944644-B2
Application number	US-201816769111-A
Country	US
Kind code	B2
Filing date	Dec 4, 2018
Priority date	Dec 5, 2017
Publication date	Apr 2, 2024
Grant date	Apr 2, 2024

Abstract

The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

First claim

The invention claimed is:

1. A T-cell genetically modified to express at least two distinct separate chimeric antigen receptors (CARs), wherein the first CAR comprises an antigen binding domain that binds specifically to CD138 and the second CAR comprises an antigen binding domain that binds specifically to CD38, wherein one of the CARs comprises an activation domain and is devoid of a costimulatory domain and the other CAR comprises a costimulatory domain and is devoid of an activation domain.

2. The T-cell of claim 1 , wherein the antigen binding domain that binds specifically to CD138 is a single chain variable fragment (anti-CD138 scFv) and the antigen binding domain that binds specifically to CD38 is a single chain variable fragment (anti-CD38 scFv).

3. The T-cell of claim 2 , wherein the anti-CD138 scFv comprises a VL domain having the amino acid sequence of SEQ ID NO: 13 and a VH domain having the amino acid sequence of SEQ ID NO: 14; and/or wherein the anti-CD38 scFv domain comprises a VL domain having the amino acid sequence of SEQ ID NO: 15 and a VH domain having the amino acid sequence of SEQ ID NO: 16, wherein the VL and the VH domains are bound by a peptide linker.

4. The T-cell of claim 1 , wherein:
(i) the first CAR comprises an activation domain and is devoid of a costimulatory domain and the second CAR comprises a costimulatory domain and is devoid of an activation domain; or
(ii) the first CAR comprises a costimulatory domain and is devoid of an activation domain and the second CAR comprises an activation domain and is devoid of a costimulatory domain.

5. The T-cell of claim 1 , characterized by at least one of:
(i) the costimulatory domain is selected from a costimulatory domain of CD28, 4-1BB, OX40, iCOS, CD27, CD80, CD70 and the activation domain is selected from an FcRγ and CD3-ζ activation domain;
(ii) the activation domain is FcRγ activation domain having the amino acid sequence of SEQ ID NO: 23 and the costimulatory domain is a costimulatory domain of CD28 having the amino acid sequence of SEQ ID NO: 22; and
(iii) the peptide linker is a peptide having the amino acid sequence of SEQ ID NO: 17.

6. The T cell of claim 1 , wherein the first CAR has the amino acid sequence of SEQ ID NO: 24, and the second CAR has the amino acid sequence of SEQ ID NO: 25.

7. The T-cell of claim 1 , comprising at least one copy of one or more DNA constructs encoding the at least two distinct separate chimeric antigen receptors (CARs), wherein the first CAR comprises an anti-CD138 scFv and the second CAR comprises an anti-CD38 scFv.

8. The T-cell of claim 7 , comprising either at least one copy of a DNA construct selected from the group consisting of:
(I) a DNA construct encoding for: (A) from 5′ to 3′, (i) a leader peptide, (ii) anti-CD138 scFv, (iii) a transmembrane domain I, (iv) a costimulatory domain or an activation domain, and (B) from 5′ to 3′ (v) a leader peptide, (vi) anti-CD38 scFv domain, (vii) a transmembrane domain II and (viii) an activation domain or a costimulatory domain; wherein (A) and (B) are separated by a self-cleaving peptide;
(II) a DNA construct encoding, from 5′ to 3′, (i) a leader peptide, (ii) anti-CD138 scFv, (iii) a transmembrane domain I, (iv) a costimulatory domain, (v) a self-cleaving peptide, (vi) a leader peptide, (vii) anti-CD38 scFv domain, (viii) a transmembrane domain II and (ix) an activation domain; and
(III) a DNA construct encoding from 5′ to 3′, (i) a leader peptide, (ii) anti-CD38 scFv, (iii) a transmembrane domain II, (iv) an activation domain, (v) a self-cleaving peptide, (vi) a leader peptide, (vii) anti-CD138 scFv domain, (viii) a transmembrane domain I and (ix) a costimulatory domain, or two different DNA constructs, wherein the first DNA construct comprises a DNA sequence encoding, from 5′ to 3′, (i) a leader peptide, (ii) anti-CD138 scFv, (iii) a transmembrane domain I and (iv) a costimulatory domain or an activation domain, and the second DNA construct comprises a DNA sequence encoding from 5′ to 3′ (i) a leader peptide, (ii) anti-CD38 scFv domain, (iii) a transmembrane domain II and (iv) an activation domain or a costimulatory domain.

9. The T-cell of claim 8 , wherein the DNA construct is characterized by at least one of:
(i) the leader peptide has the amino acid sequence of SEQ ID NO: 20;
(ii) the activation domain has the amino acid sequence of SEQ ID NO: 23;
(iii) the costimulatory domain has the amino acid sequence of SEQ ID NO: 22;
(iv) the anti-CD138 scFv domain has the amino acid sequence of SEQ ID NO: 18;
(v) the anti-CD38 scFv domain has the amino acid sequence of SEQ ID NO: 19;
(vi) the self-cleaving peptide is selected from the peptide having the amino acid sequence of SEQ ID NO: 26, IRES peptide;
(vii) the leader peptide is encoded by the DNA sequence set forth in SEQ ID NO: 39;
(viii) the anti-CD138 scFv is encoded by the DNA sequence set forth in SEQ ID NO: 28;
(ix) the anti-CD38 scFv is encoded by the DNA sequence set forth in SEQ ID NO: 29;
(x) the costimulatory domain is encoded by the DNA sequence set forth in SEQ ID NO: 30; and
(xi) the activation domain is encoded by the DNA sequence set forth in SEQ ID NO: 31.

10. The T-cell of claim 7 , comprising (i) at least one copy of a DNA construct having the DNA sequence of SEQ ID NO: 34; or (ii) comprising at least one copy of a DNA construct comprising the DNA sequence of SEQ ID NO: 32 and at least one copy of a DNA construct comprising the DNA sequence of SEQ ID NO: 33.

11. The T-cell of claim 1 , wherein the T cell is selected from a CD4+ T-cell and a CD8+ T-cell.

12. A pharmaceutical composition comprising a plurality of the T cell according to claim 1 , and a pharmaceutically acceptable carrier.

13. A method of treating multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of a plurality of the T cell according to claim 1 .

14. A DNA construct encoding an amino acid sequence selected from the group consisting of:
(A) from 5′ to 3′, (i) a leader peptide, (ii) anti-CD138 scFv, (iii) a transmembrane domain I, (iv) a costimulatory domain or; an activation domain, (v) a self-cleaving peptide, (vi) a leader peptide, (vii) anti-CD38 scFv domain, (viii) a transmembrane domain II, and (ix) a costimulatory domain or an activation domain;
(B) from 5′ to 3′, (i) a leader peptide, (ii) anti-CD38 scFv domain, (iii) a transmembrane domain II, (iv) an activation domain or a costimulatory domain, (v) a self-cleaving peptide, (vi) a leader peptide, (vii) anti-CD138 scFv, (viii) a transmembrane domain I, and (ix) a costimulatory domain or an activation domain;
(C) from 5′ to 3′, (i) a leader peptide, (ii) anti-CD138 scFv, (iii) a transmembrane domain I, (iv) a costimulatory domain, (v) a self-cleaving peptide, (vi) a leader peptide, (vii) anti-CD38 scFv domain, (viii) a transmembrane domain II, and (ix) an activation domain; and
(D) from 5′ to 3′, (i) a leader peptide, (ii) anti-CD38 scFv, (iii) a transmembrane domain II (iv) an activation domain, (v) a self-cleaving peptide, (vi) a leader peptide, (vii) anti-CD138 scFv domain, (viii) a transmembrane domain I, and (ix) a costimulatory domain.

15. The DNA construct according to claim 14 , characterized by at least one of:
(i) the self-cleaving peptide has the amino acid sequence of SEQ ID NO: 26;
(ii) the leader peptide has the amino acid sequence of SEQ ID NO: 20;
(iii) the activation domain has the amino acid sequence of SEQ ID NO: 23;
(iv) the costimulatory domain has the amino acid sequence of SEQ ID NO: 22;
(v) the anti-CD138 scFv domain has the amino acid sequence o

Assignees

• Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct
• Yeda Res & Dev

Inventors

• Eshhar Zelig
• Waks Tova
• Globerson Levin Anat
• Rawet Slobodkin Moran

Classifications

• A61K40/4261

  Proteoglycans, e.g. glypican, brevican or CSPG4 · CPC title

• A61K40/4222

  CD38 not IgG · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title